

iTrack[™] Canaloplasty to be Featured at the International Congress of German Ophthalmic Surgery (DOC) 2024

California, USA, June 6, 2024 - Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary iTrack™ canaloplasty technology will be featured in numerous presentations and posters during the official scientific program of the 36th International Congress of German Ophthalmic Surgery (DOC), taking place in Nuremberg, June 20-22, 2024.

A summary of the iTrack[™] official DOC scientific programming is outlined below:

Podium Presentations:



Friday, June 21, 2024



Saal Budapest

Norbert Koerber (Germany); Simon Ondrejka (Germany)

6-Year Efficacy and Safety of iTrack Ab-interno Canaloplasty in Primary **Open-Angle Glaucoma**

Time: 17:12 - 17:19

Karl Mercieca (Germany); David Lubeck (USA); Keith Barton (UK); Nathan Kerr (East Australia)

24-Month Results of iTrack Global Data Registry to Support the Role of **Canaloplasty for Treatment of Glaucoma**

Time: 17.19 - 17.26

Karl Mercieca (Germany); David Lubeck (USA); Keith Barton (UK); Nathan Kerr (Australia)

Canaloplasty performed with the iTrack microcatheter to reduce IOP in uncontrolled glaucoma eyes


Time: 17.26 - 17.33



Podium Presentations (cont.):



Friday, June 21, 2024



Simon Ondrejka (Germany); Norbert Koerber (Germany)

Efficacy, and Safety of Ab-interno Canaloplasty using iTrack Advance in **Primary Open-Angle Glaucoma**

Time: 17.33 - 17.40

Karsten Klabe (Germany); David Lubeck (USA); Keith Barton (UK); Nathan Kerr (Australia)

Multicenter Canaloplasty Data Registry – Outcomes of Ab-Interno Canaloplasty Across Different Glaucoma Types and Severity 17.40 - 17.47

Course:



Saturday, June 22, 2024

Saal Krakau

Norbert Koerber (Germany)

Ab-interno and ab-externo canaloplasty

Time: 12.33 - 12.46

Full session details can be accessed via the DOC program: https://www.doc-nuernberg.de/content.php?flDay=2024-06-22

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont,



California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

For additional information about canaloplasty and the new *iTrack*[™] *Advance*, including safety information, please visit: https://itrack-advance.com

The iTrack™ Advance has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open angle glaucoma.

The iTrack™ Advance has been cleared for the indication of fluid infusion and aspiration during surgery. The iTrack™ Advance canaloplasty device has been cleated for the indication of catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

CONTACT DETAILS:

For media enquiries, please contact:
Giorgio Pirazzini, GP Communications – giorgio@gpcommunications.eu

For corporate enquiries, please contact:

Kate Hunt, Nova Eye Chief Commercial Officer - khunt@nova-eye.com